In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Atossa Therapeutics (ATOS – Research Report), with a price target of $4.00. The company’s shares opened today at $1.20.
According to TipRanks, McCarthy is an analyst with an average return of -28.0% and a 25.15% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group, Lineage Therap, and Achieve Life Sciences.
Atossa Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $4.00.
See Insiders’ Hot Stocks on TipRanks >>
Based on Atossa Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $6.28 million. In comparison, last year the company had a GAAP net loss of $4.79 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.
Read More on ATOS:
- Atossa Therapeutics Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical Trial
- Atossa reports 170 patients enrolled in Phase 2 Karisma-Endoxifen trial
- Atossa Therapeutics Announces Sponsored Research Agreement with Weill Cornell Medicine to Address Treatment Challenges in Triple Negative Breast Cancer
- Atossa Therapeutics enters sponsored research agreement with Weill Cornell
- Biotech Alert: Searches spiking for these stocks today
